Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

PXS-5505 - Pharmaxis

Jakafi (ruxolitinib) - Novartis, Incyte

Menerba (MF101) - Bionovo

https://ash.confex.com/ash/2022/webprogram/Paper158344.html

Ross Baker, MBBS, BMedSc1*, Jana Baskar, MBBS, MMedSc2*, Brett Charlton, MD, PhD2*, Gabriela S. Hobbs, MD3, Wolfgang Jarolimek, PhD2*, Sung-Eun Lee, MD4*, Lucia Masarova, MD5 and Anne-Marie Watson, MBBS, FRACP, FRCPA6

Nov 4, 2022